COMMUNIQUÉS West-GlobeNewswire

DentaBiome Details Oral Postbiotic Formula and Sourcing Amid 2026 Dental Caries Research
03/08/2026
Berry Frost chewable formula pairs Lactobacillus postbiotic strains, xylitol, cranberry extract and purple carrot powder in a GMP-certified US facility. Tallmadge, OH, Aug. 03, 2026 (GLOBE NEWSWIRE) -- These statements [...]
Direct Meds Expands DirectMax Patient Access and Prescription Fulfillment Information
03/08/2026
Direct Meds has expanded the patient information available for DirectMax, including its online clinical-review process, compounded-medication status, licensed-pharmacy fulfillment structure, recurring-plan terms and [...]
Zealand Pharma - Transactions related to share buy-back program (week 31, 2026)
03/08/2026
Company announcement No. 36 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 31, 2026) Copenhagen, Denmark, August 3, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 31 - 2026
03/08/2026
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 27 juillet au 31 juillet 2026 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2026
03/08/2026
Aggregated presentation by day and by market Weekly report on share repurchases from 27th July to 31st July 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument [...]
Carbios fait un point d’étape sur le financement de son projet d’usine à Longlaville
03/08/2026
Carbios réaffirme son ambition de construction de l’usine de Longlaville Des étapes importantes en vue de la sécurisation du financement du projet ont été franchies L’objectif annoncé d’un closing d’ici le 30 septembre [...]
Carbios provides an update on the financing of its Longlaville plant project
03/08/2026
Carbios reaffirms its commitment to building the Longlaville plant. Significant milestones have been achieved toward securing the project’s financing. While significant progress has been made, the previously announced [...]
A Race Against Blindness Launches New Research Grants Program to Accelerate Treatments for Inherited Retinal Diseases and Bardet-Biedl Syndrome
03/08/2026
New grant program announced at the Bardet-Biedl Syndrome Foundation Annual Conference invites researchers worldwide to apply for funding GILBERT, Ariz., Aug. 03, 2026 (GLOBE NEWSWIRE) -- A Race Against Blindness today [...]
CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
03/08/2026
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Alejandra [...]
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
03/08/2026
The open-label Phase 2 trial will evaluate ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq [...]
Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
03/08/2026
Company to hold a conference call at 8:30 a.m. ET DURHAM, N.C., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative [...]
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
03/08/2026
RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027 Patient dosing initiated in Phase 1 multiple-ascending dose trial of DT-818 [...]
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH
03/08/2026
Global registrational study designed to evaluate pemvidutide on fibrosis improvement, MASH resolution, and clinical outcomes Initiation marks advancement of Altimmune's lead program into late-stage development following [...]
electroCore to Participate in Upcoming Investor Conferences
03/08/2026
ROCKAWAY, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the following [...]
Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation
03/08/2026
Nominates Two New Independent Directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, Who Bring Deep, Relevant Experience in Life Sciences Mr. Patel and Dr. Senderowicz to Stand for Election at 2026 Annual Meeting with [...]
Neuronetics and Jorey Chernett Announce Shared Vision
03/08/2026
Chernett Affirms Comfort with the Company’s Capital Position and Confidence in Management’s Execution Establishes Path Towards Neuronetics Board Representation MALVERN, Pa., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics [...]
Carlsmed Announces Favorable Reimbursement for aprevo® lumbar Procedures
03/08/2026
Centers for Medicare & Medicaid Services (CMS) Fiscal Year 2027 Inpatient Final Rule creates three new Medicare Severity-Diagnosis Related Groups (MS-DRGs), with favorable reimbursement for Carlsmed aprevo® Lumbar [...]
Mesa Labs Announces First Quarter Financial Results Release Date and Inaugural Earnings Conference Call
03/08/2026
LAKEWOOD, Colo., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”), a global leader in the design and manufacture of life science tools and critical quality [...]
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
03/08/2026
CAMBRIDGE, Mass. and DALLAS and TAMPA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc., (Nasdaq: TSHA) (Taysha), a clinical-stage biotechnology company focused on developing adeno-associated virus ( [...]

Pages